Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 11,335 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Meningeal Neoplasms
Interventions: Intrathecal (injected into the spinal fluid) DepoCyt, Intrathecal methotrexate, Intrathecal cytarabine (also known as ara-C); Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 21
States / cities: Phoenix, Arizona • Berkeley, California • Los Angeles, California + 18 more

Conditions: Wegener's Granulomatosis
Interventions: Abatacept; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 533
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more

Conditions: Sarcoma
Interventions: Trivalent ganglioside vaccine, OPT-821; Biological
Lead sponsor: MabVax Therapeutics, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 13
States / cities: Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 10 more

Conditions: Partial Seizures
Interventions: Divalproex Sodium (Depakote Sprinkle Capsules); Drug
Lead sponsor: Abbott; Industry
Eligibility: 3 Years to 10 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 10
States / cities: Northport, Alabama • Phoenix, Arizona • Tampa, Florida + 7 more

Conditions: Colonic Diseases, Rectal Diseases
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cytomegalovirus Infection
Interventions: Placebo, Valganciclovir; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 30 Days
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more

Conditions: Glioblastoma
Interventions: NeuroBlate System, Radiation therapy and temozolomide; Device · Drug
Lead sponsor: Monteris Medical; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: St Louis, Missouri • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more

Conditions: COVID-19
Interventions: LY3819253, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 42
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more

Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions: Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Questionnaire Administration; Drug · Biological · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 795
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 510 more

Conditions: Non Small Cell Lung Cancer, Lung Cancer, Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer
Interventions: S-3304, Chemo-irradiation; Drug · Other
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 5
States / cities: La Jolla, California • Washington D.C., District of Columbia • Kansas City, Kansas + 2 more

Conditions: IBD, Crohn Disease, Ulcerative Colitis
Interventions: Breath Test; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mitral Valve Insufficiency, Coronary Artery Disease
Interventions: MV Repair, MV Replacement, CABG; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more

Conditions: Clostridium, Difficile, Fidaxomicin, Vancomycin
Interventions: Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more

Conditions: Parkinson's Disease
Interventions: PYM50028, Placebo; Drug
Lead sponsor: Phytopharm; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more

Conditions: Stroke, Acute Ischemic Stroke
Interventions: Repinotan HCl (BAYX3702), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 28
States / cities: Los Angeles, California • Oceanside, California • San Diego, California + 25 more

Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 32
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 27 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 53
States / cities: Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more

Conditions: Pouchitis, Crohn's Disease, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Pouch, Ileal
Interventions: Mesenchymal Stem Cells (MSCs); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Leiomyosarcoma
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more

Conditions: Cardiovascular Disease, Hypertension, Care Coordination, HIV Treatment Cascade
Interventions: Intervention group, Education control group; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Decatur, Georgia • Baltimore, Maryland • Durham, North Carolina + 1 more

Conditions: Malnutrition
Interventions: Natural Orifice Translumenal Endoscopic Surgery; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Euvolemic Hyponatremia, Hypervolemic Hyponatremia
Interventions: Not listed
Lead sponsor: Otsuka America Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 5,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 72
States / cities: Azusa, California • Inglewood, California • Los Angeles, California + 58 more

Conditions: Von Willebrand Disease (VWD)
Interventions: rVWF, rFVIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 0 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more

Search by objective public record fields.

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

A Study for Treatment of Partial Seizures in Children

Assessing Infectious Risk and Visceral Closure in Natural Orifice Translumenal Endoscopic Surgery (NOTES)

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease

Long Term Follow Up for CTSN Mitral Valve Repair Studies

Optimal Treatment for Recurrent Clostridium Difficile

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

Repinotan in Patients With Acute Ischemic Stroke

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

Stem Cells for the Treatment of Pouchitis

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention

Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG "Rescue"

Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)